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ABSTRACT
Aims The purpose of this study was to clinically
validate an individually planned treatment regimen for
neovascular age-related macular degeneration (nAMD),
termed, observe and plan. This regimen was based on
the predictability of an individual’s need for retreatment
and aimed to reduce the clinical burden, while obtaining
good functional results.
Methods This was a prospective case series that
included 104 patients (115 eyes) with treatment-naive
nAMD. Following three loading doses of ranibizumab,
monthly observation visits allowed the disease recurrence
interval to be determined. The recurrence interval was
reduced by 2 weeks to give the retreatment interval for
the next three injections. Periodical control visits (at least
every 6 months) allowed the effectiveness of the
treatment to be assessed and individual intervals
adjusted.
Results Mean visual acuity (VA) improved by 8.7 and
9.8 letters in months 3 and 12, respectively. The mean
number of injections during the 12-month study was
7.8, while the mean number of ophthalmic examinations
between months 3 and 12 was 3.97. The mean
treatment interval after the loading doses was
1.97 months.
Conclusions The observe-and-plan regimen
signiﬁcantly improved VA. This was obtained with fewer
clinic visits compared with other regimens, which could
ease the burden of nAMD treatment.
Trial registration number Commission cantonale
(VD) d’éthique de la recherché Clinique, Université de
Lausanne, Protocole 351/11.
INTRODUCTION
In 2002, advanced age-related macular degener-
ation (AMD) was the leading cause of irreversible
vision loss in individuals aged 50 years and older in
industrialised countries.1 Large multicentre, rando-
mised controlled trials have shown that monthly
intravitreal injections of ranibizumab, a speciﬁc
recombinant, humanised IgG monoclonal antibody
that neutralises all active forms of VEGF-A,2 signiﬁ-
cantly improve visual acuity (VA) in neovascular
AMD (nAMD) compared with sham treatment,3 or
photodynamic therapy.3–5 However, monthly injec-
tions place a heavy burden on the chronic care
management of patients with nAMD.6
To alleviate this burden, more recent clinical
trials have examined alternative treatment regi-
mens. A regimen of injections every 3 months
resulted in the loss of initial VA improvement, sig-
niﬁcantly inferior to monthly injections.7–9 An
individualised dosing regimen, pro re nata (PRN),
was investigated in the PrONTO,10 11 CATT,12 13
IVAN14 and HARBOR15 clinical trials, during
which it was found to be comparable to monthly
dosing. Individualised dosing regimens are used fre-
quently in clinical practice10 11 16–20 to reduce
injection frequency while still obtaining good func-
tional results compared with monthly retreat-
ment.12 14 15 However, with the exception of the
treat and extend regimen (TER),17 these dosing
schedules still require monthly monitoring to
detect disease recurrences as early as possible.
We recently published the results from a study
that evaluated the predictability of the need for
retreatment across a group of 39 individuals with
treatment-naive nAMD.21 We demonstrated the
presence of a highly regular, predictable, individual
pattern in the need for retreatment, with relatively
small ﬂuctuations over the course of 12 months.21
The present study aims to convert these results into
a clinically relevant treatment protocol, using a
planned treatment regimen based on the measure-
ment of an individual’s ﬁrst disease recurrence
interval. If successful, this novel treatment regimen
will reduce the number of clinic visits and injec-
tions while still maintaining VA improvements
throughout the follow-up period.
METHODS
This prospective study was undertaken in the
medical retina department of a single tertiary refer-
ral centre (University Eye Hospital Jules Gonin in
Lausanne, Switzerland). The study was approved by
the local ethics committee (Commission d’éthique
de la recherche clinique, Université de Lausanne)
and adhered to the tenets of the Declaration of
Helsinki. All patients gave written informed
consent.
Patient selection
The study enrolled a consecutive series of patients
(prospective aim was 100 patients) aged 50 years
or older, with newly diagnosed, treatment-naive
nAMD and active subfoveal choroidal neovasculari-
sation (CNV), as conﬁrmed on ﬂuorescein angiog-
raphy by a retinal specialist (AA or IM). Additional
inclusion criteria were: best corrected VA (BCVA)
from 20/25 to 200/400, a maximum lesion size of
12 disc areas, and informed consent. Exclusion cri-
teria included: subfoveal atrophy or ﬁbrosis, poly-
poidal choroidal vasculopathy, CNV resulting from
a disease other than AMD, any other macular path-
ology, a history of any macular treatment or
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vitrectomy, aphakia, history of uveitis or active ocular inﬂamma-
tion in the study eye, any other vision-affecting ocular disorder,
and the inability to obtain retinal images of sufﬁcient quality.
Therefore, the inclusion and exclusion criteria were similar to
the multicentre phase III trials,3 4 10 with the exception of a
slightly enlarged spectrum for BCVA.
Clinical investigations
Baseline examination and all subsequent follow-up visits
included measurement of BCVA on the Early Treatment of
Diabetic Retinopathy Study (ETDRS) chart, slit lamp examin-
ation, measurement of intraocular pressure, dilated fundus
examination, and spectral domain OCT (SD-OCT; Cirrus, Carl
Zeiss Meditec, Oberkochen, Germany). The following add-
itional examinations were performed at baseline and after
3 months, using the Topcon TRC-50IX (Tokyo, Japan): fundus
autoﬂuorescence imaging, ﬂuorescein angiography, and indocya-
nine green angiography (the latter at baseline only).
OCT analysis
A macular cube (512×126) scan captured using an SD-OCT
Cirrus machine was used for baseline examination and all
follow-up visits. The macular thickness map was acquired with
the integrated software 6.0.0.599, which centred on the auto-
matically identiﬁed foveal pit and was manually corrected if
needed. Central retinal thickness (CRT) was measured in the
central 1 mm2 subﬁeld. All OCT scans were qualitatively evalu-
ated for the presence or absence of intraretinal or subretinal
ﬂuid.
Observe-and-plan regimen
The concept of the observe-and-plan regimen was to evaluate
the individual need for retreatment in an observation phase
after three loading doses, and then to apply the treatment in an
individually adapted treatment plan of a series of injections with
ﬁxed intervals. The interval was regularly adjusted for the subse-
quent treatment plans. The details of the regimen (illustrated in
ﬁgure 1) were as follows:
All patients underwent an initial loading dose of three-
monthly intravitreal injections of 0.5 mg ranibizumab (Lucentis,
Novartis Pharma AG, Basel, Switzerland). The loading dose
was followed by monthly observation visits (with extension
allowed every 1.5 months and 2 months after 3 months and
6 months since the last injection, respectively), which allowed
the determination of the interval from the third injection until
ﬁrst signs of exudative activity on SD-OCT or fundus examin-
ation. Based on this interval which was shortened by 2 weeks in
an attempt to keep the macula dry, an individualised ﬁxed treat-
ment plan (without intermittent ophthalmic examination) was
established for the next three injections. The available choice of
intervals was limited to 1–3 months. Longer intervals were not
allowed because of unavailable data about their reliability.21
Therefore, recurrences that were observed at 4 months or more
since last injection, were an indication to treat every 3 months.
A recurrence after 2 months and 3 months was an indication
for retreatment every 1.5 and 2.5 months, respectively, while
eyes with exudative signs already at 1 month after last injection
continued on the monthly retreatment regimen for the next
three injections. Because of the concern of undiagnosed inter-
mittent recurrence once the individualised ﬁxed treatment plan
has been launched, we decided to see the patient at least every
6 months for ophthalmic examination. Therefore, only two
injections were planned for intervals of 2.5 or 3 months, with
an assessment visit after 5 months and 6 months, respectively.
Figure 1 gives an overview over the available choice of ﬁxed
treatment series (3 times 1, 1.5, or 2 months; twice 2.5 or
3 months).
Figure 1 Treatment algorithm of this observe-and-plan regimen with
ranibizumab for neovascular age-related macular degeneration. Every
patient received the initial loading dose of 3 ranibizumab injections at
1-month intervals, (abbreviated as 3×1). Subsequently, ﬁndings on
optical coherence tomography deﬁned the pathway in the algorithm;
3×1*=three injections at ﬁxed interval of 1 month and assessment visit
1 month after the third injection (total assessment interval 3 months);
3×1.5*=three injections at ﬁxed interval of 1.5 months and assessment
visit 1.5 months after the third injection (total assessment interval
4.5 months); 3×2*=three injections at ﬁxed interval of 2 months and
assessment visit 2 months after the third injection (total assessment
interval 6 months); 2×2.5*=two injections at ﬁxed interval of
2.5 months and assessment visit 2.5 months after the third injection
(total assessment interval 5 months); 2×3*=two injections at ﬁxed
interval of 3 months and assessment visit 3 months after the third
injection (total assessment interval 5 months). #The possible treatment
intervals for the ﬁxed injection plan ranged from a minimum of
1 month to a maximum of 3 months. In case of an injection—
recurrence interval more than 3 months—the patient received the
treatment plan of two injections every 3 months (2×3 months). †Empty
arrow=decision in case of exudative signs on ophthalmic examination,
full arrow=decision in case of dry macula on ophthalmic examination.
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Follow-up assessment visits were performed with the same
interval from the last injection of the series, and allowed for a
dynamic feedback mechanism and adjustment of the intervals in
the subsequent treatment plans. In the presence of exudative
signs, the future treatment interval was shortened by 2 weeks
(to a minimum of 1 month). In the absence of exudative signs,
the future treatment interval was extended by 2 weeks (to a
maximum of 3 months). However, if the treatment interval was
successfully lengthened to 3 months, and the macula remained
dry, the patient was given the option of continuing to receive a
series of two injections every 3 months, or being monitored
every 1.5 months. In case of intermittent or severe exudative
recurrence, the protocol allowed shortening of the interval at
the investigator’s discretion.
Clinical outcome analysis
Clinical outcome measures included the following: mean BCVA
change over time with an endpoint at 12 months; the propor-
tion of eyes that lost <15 letters; the proportion of eyes that
gained ≥15 letters; mean CRT change; the initial interval after
the loading dose; the mean treatment interval during the main-
tenance phase; the number of visits and injections over
12 months. The last available BCVA and CRT measurements
were carried forward to the last visit to allow for statistical ana-
lysis. However, missing data for patients who were lost to
follow-up were taken into account until their last visit only.
These patients were not included in the analysis of stability
versus changing need for retreatment over time. An economic
assessment of this regimen in comparison with other variable
treatment protocols was completed (see online supplementary
methods).
Statistical results were considered signiﬁcant at a level of sig-
niﬁcance of 0.05.
RESULTS
Baseline characteristics
A total of 115 eyes from 104 patients were included in this
study (107 eligible patients; 3 patients did not give informed
consent); 102 patients (113 eyes) completed 12 months
follow-up (1 patient was lost after 10 months for departure to
another country, 1 patient changed hospitals after 6 months).
The mean age was 79.5 years (SD 7.8, range 59–95; table 1)
and included 66 women (63.5%). All patients were Caucasian.
Improvements in VA and CRT
Mean BCVA improved signiﬁcantly from 58.3 to 67.0 ETDRS
letters (+8.7 compared with baseline; p<0.0001, paired t test)
at month 3, and this increase was maintained to month 12
(+9.8 letters) (ﬁgure 2; upper graph). By month 12, 98% of
eyes had lost less than 15 ETDRS letters (3 lines), 84% had
gained ≥0 letters, and 30% had gained ≥15 ETDRS letters.
Loss of more than 15 letters ETDRS was related to increasing
atrophy. OCT measurements demonstrated that mean CRT
improved from 342 μm (SD 85, range 186–689) at baseline by a
mean of −97 and −99 μm at months 3 and 12, respectively
(ﬁgure 2; lower graph).
Factors impacting upon clinical burden
The mean number of injections performed during the ﬁrst
12 months was 7.8 (SD 3.1, range 3–13), including the ﬁrst
three loading doses. Between months 3 and 12, the mean
number of clinic visits, with ophthalmic examinations, was 3.97
(SD 1.40, range 2–8; ﬁgure 3) and the mean treatment interval
was 1.97 months. After the loading doses, 35% of eyes showed
exudative signs 1 month after the third injection. Half these
eyes (17%) did not show absence of subretinal and intraretinal
ﬂuid on SD-OCT until month 12, and therefore remained on
this monthly dosing regimen. The observation phase resulted in
a 1.5, 2 to 2.5, and 3 months interval in the ﬁrst retreatment
plan for 19%, 16% and 18% of eyes, respectively. The macula
remained exudation-free until month 12 in 12% of eyes.
An explorative analysis of potentially interval-associated
factors (age, lesion size, lesion type, baseline CRT, baseline VA)
remained negative. However, the numbers included are insufﬁ-
cient for this analysis. Interestingly, 8 out of the 11 patients
with bilateral eye inclusion (72.7%) showed highly symmetric
need for retreatment with a maximum of one injection differ-
ence in the ﬁrst year. This might suggest that systemic factors,
rather than ocular factors, play a more important role for the
need of retreatment.
Within the follow-up period, the treatment interval remained
stable (ie, within ±2 weeks) in 80% of eyes. The interval was
progressively lengthened in 15% of eyes, while 5% of eyes
needed a shortening of the interval by more than 2 weeks as
compared to the ﬁrst measured interval. The direct medical cost
of this observe-and-plan regimen was near-equivalent to the
variable dosing arm of the CATT protocol (see online supple-
mentary table S1).
Table 1 Comparison of baseline characteristics between different ranibizumab treatment regimens for nAMD
MARINA3 ANCHOR4 CATT12 TER17 Observe and plan*
Gender (% female) 63.3 46.4 61.9 66.3 63.5
Race (% Caucasian) 96.7 97.1 98.6 100 100
Age (mean±SD) 77±8.0 76±8.6 79.3±7.8 80.6±6.6 79.5±7.8
VA mean (median) na na 20/60+1 20/135 (20/100) 20/80+3 (20/60+3)
VA≤20/200 (%) 12.9 23.0 6.8 22.8 11.3
20/200<VA<20/40 72.1 72.7 62.3 67.4 58.3
VA≥20/40 15.0 4.3 30.9 9.8 30.4
Predominately classic CNV lesion (%) 0 96.4 na 19.6 24.4
Minimally classic CNV lesion (%) 37.9 3.6 na 28.7 10.4
Occult with no classic CNV (%) 62.1 0 na 52.5 45.2
Retinal angiomatous proliferation (%) na na na na 20.0
Size of lesion (disc areas) 4.5 1.79 2.7 2.6 2.48
*Treatment regimen of this study.
CNV, choroidal neovascularisation; na, not applicable; nAMD; neovascular age-related macular degeneration; TER, treat and extend regimen; VA, visual acuity.
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No severe ocular or systemic adverse events were reported
during the course of this study.
DISCUSSION
In the present study, we demonstrated the success of an indi-
vidually tailored observe-and-plan regimen, which dramatically
reduced the number of clinic visits with ophthalmic examina-
tions, yet obtained good functional outcomes over 12 months
through the administration of the appropriate number of injec-
tions. These results are important in two ways.
First, the large reduction of clinic visits that require detailed
ophthalmologic examinations, to a mean of just below four in
the ﬁrst year of the study, should allow clinical teams to manage
the treatment burden of nAMD more efﬁciently, compared with
the 12 visits required by PRN regimens12 14 15 or the ∼8 visits
involved for TER.17 In fact, these examination visits are the
time-consuming part of patient care, and their number deter-
mines the clinical burden. Clinical burden is an important, but
often ignored, factor in determining the optimal treatment
regimen to use, and unnecessary examinations waste clinical
resources that could be better applied elsewhere.6 With
observe-and-plan regimens, two to three more patients per day
may be managed in clinics as compared with PRN and TER
treatment routines. However, the number of injections remained
similar within these three regimens (observe-and-plan, PRN and
TER), as observe-and-plan was designed to anticipate each indi-
vidual’s requirement for injections.
Second, the results of this study support that individualised
predicting future treatment needs for up to 6 months, on the
basis of the measurement of the ﬁrst recurrence interval, com-
bined with a dynamic feedback evaluation loop (ie, assessment
visits; ﬁgure 1), provides adequate treatment for nAMD. The
ﬁnal visual outcome and, particularly, the maintenance of the
initial visual gain (ﬁgure 2), served as validation of this regimen.
It has been repeatedly observed that late retreatment8 9 and
PRN9 18 22 23 are associated with secondary loss of the initial
visual improvement to various degrees. While the initial improve-
ment in VA at month 3—after the three loading doses—reﬂects
the potential of the photoreceptors to recover function, the most
important phase for the validation of any retreatment regimen is
Figure 2 Mean change of best
corrected visual acuity (BCVA; upper
graph) and of central retinal thickness
(CRT) measured using optical
coherence tomography (lower graph)
of all study eyes treated with
ranibizumab for neovascular
age-related macular degeneration
following an observe and plan regimen
during the 12 month study period.
Error bars represent SE of the mean.
Figure 3 Distribution of the number of clinic visits with ophthalmic
examination between months 3 and 12.
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the maintenance phase after month 3. Thus far, various studies
have concluded that strict monthly visits are mandatory in a
PRN regimen to maintain the initial VA improvement past
month 3.10 11 23 By contrast, our results that show slight
improvement between month 3 and month 12 (ﬁgure 2), suggest
that individually planned injection schedules using the predict-
ability of need for retreatment may allow similarly good out-
comes, even though far fewer examination visits are required.
Clinicians may be concerned about a possible risk of under-
treatment of patients with nAMD, due to the departure from
monthly ophthalmic examinations. Data presented herein argue
against this concern in three ways. First, throughout the
follow-up assessment visits, no patient presented with a strong
exudative recurrence, which indicated that the planned intervals
were appropriately tailored to treat nAMD in each individual.
Second, only 2% of eyes lost more than three lines of BCVA
after 12 months, which is comparable with the MARINA and
ANCHOR trials, where this number was about 5%.3 4 The
third observation was that only 5% of patients actually required
a reduction of their retreatment interval compared with that ini-
tially estimated for them. Observe-and-plan, therefore, did not
lead to the undertreatment of patients in this study.
In conjunction with the beneﬁts of the regimen, there was
one potential limitation. The mean number of reinjections in
the ﬁrst year was slightly higher than in the PRN arms of the
multicentre studies (7.8 instead of 6.9–7.7),12 13 15 possibly due
to the ﬁxed dosing phases, and partially due to sensitive retreat-
ment criteria used in this study (SD-OCTwas only used in the
HARBOR trial).
We acknowledge that the present study was uncontrolled. The
regimen was validated only in that it maintained the VA gain
after month 3 through to month 12.
In conclusion, chronic care management of patients with
nAMD, using the observe-and-plan regimen, based on the predict-
ability of the need for retreatment, resulted in signiﬁcant and
maintained VA improvement. The gains in VA were achieved with
a number of injections comparable with other variable dosing regi-
mens (PRN or TER), but required fewer clinic visits with ophthal-
mic examinations. This variable dosing regimen has the potential
to ease the burden of nAMD treatment management on institu-
tions and doctors, and may help with patient compliance.
However, long-term data beyond a 12-month follow-up period,
and direct comparison with the gold standard of monthly retreat-
ment, are needed in order to deﬁnitively conﬁrm its value.
Correction notice This article has been corrected since it was published Online
First. In the Results section of the Abstract, the value 2.08 has been changed to
1.97 in the sentence ‘The mean treatment interval after the loading doses was 1.97
months.’
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